Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01631331 · ClinicalTrials.gov registry record · Early Phase 1
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
A Early Phase 1 study, sponsored by Stanford University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT01631331: Completed Early Phase 1 study, sponsored by Stanford University.
NCT01631331 is a Early Phase 1 study that has completed, run by Stanford University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01631331, a Early Phase 1 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.
Interventions
- DRUG vismodegib
- PROCEDURE Mohs surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-06 |
| Est. Completion | 2016-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01631331
The ClinicalTrials.gov registry entry for NCT01631331 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vismodegib is the first listed.
NCT01631331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01631331 about?
NCT01631331 is a clinical study titled "Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)". The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.
What is the current status of trial NCT01631331?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2012-06. Estimated completion is 2016-05-31.
What interventions are being tested in trial NCT01631331?
The interventions under investigation include: vismodegib (DRUG), Mohs surgery (PROCEDURE).
Who is sponsoring clinical trial NCT01631331?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.